


RECEIVED

NOV 08 2001

NOV 05 2001

RECEIVED



Please type a plus sign (+) inside this box

Copy #9

Approved for use through 10/31/2002. OMB 0654-0045
 U.S. Patent and Trademark Office; U.S. DEPARTMENT OF COMMERCE

POWER OF ATTORNEY OR AUTHORIZATION OF AGENT	Application Number	09/580,015
	Filing Date	May 26, 2000
	First Named Inventor	Dale B. Schenk
	Title	PREVENTION AND TREATMENT OF AMYLOIDOGENIC DISEASE
	Group Art Unit	1641
	Examiner Name	Unassigned.
	Attorney Docket Number	15270J-004750US

I hereby appoint:

☒ Practitioners at Customer Number

20350

 Place Customer
 Number Bar Code
 Label here

☐ Practitioner(s) named below:

Name	Registration Number

 as my/our attorney(s) or agent(s) to prosecute the application identified above, and to transact all
 business in the United States Patent and Trademark Office connected therewith.

Please change the correspondence address for the above-identified application to:

☐ The above-mentioned Customer Number.

OR

☐ Practitioners at Customer Number

<input type="checkbox"/> Firm or Individual Name				
Address				
Address				
City	State	ZIP		
Country				
Telephone	Fax			

I am the:

☐ Applicant/Inventor.

☒ Assignee of record of the entire interest. See 37 CFR 3.71.

Statement under 37 CFR 3.73(b) is enclosed. (Form PTO/SB/96).

SIGNATURE of Applicant or Assignee of Record

Name	Neuralab Limited, by: Kevin Insley, Vice President
Signature	<i>[Signature]</i>
Date	AUGUST 31, 2001

 NOTE: Signatures of all the inventors or assignees of record of the entire interest or their representative(s) are required.
 Submit multiple forms if more than one signature is required, see below*.

☒ *Total of 1 form is submitted.

Burden Hour Statement: This form is estimated to take 3 minutes to complete. Time will vary depending upon the needs of the individual case. Any
 Comments on the amount of time you are required to complete this form should be sent to the Chief Information Officer, U.S. Patent and Trademark
 Office, Washington, DC 20231. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Assistant Commissioner for
 Patents, Washington, DC 20231.
 PA 3167760 v1

 RECEIVED
 SEP 26 2001
 TC 1700

RECEIVED

NOV 08 2001

NOV 05 2001


RECEIVED

TECH CENTER 16002900

Please type a plus sign (+) inside this box



Approved for use in paper applications filed on or after 10/1/2002, OMB 1650-0046
U.S. Patent and Trademark Office, U.S. DEPARTMENT OF COMMERCE
Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it displays a valid OMB control number.



POWER OF ATTORNEY OR AUTHORIZATION OF AGENT

Application Number	09/580,015
Filing Date	May 26, 2000
First Named Inventor	Dale B. Schenk
Title	PREVENTION AND TREATMENT OF AMYLOIDOGENIC DISEASE
Group Art Unit	1641
Examiner Name	Unassigned.
Attorney Docket Number	15270J-004750US

I hereby appoint:

☐ Practitioners at Customer Number

OR

☒ Practitioner(s) named below:

Place Customer
Number Bar Code
Label here

Name	Registration Number
Nina M. Ashton	37,273
Jean M. Duvall	32,731
Lisabeth F. Murphy	31,547

as my/our attorney(s) or agent(s) to prosecute the application identified above, and to transact all business in the United States Patent and Trademark Office connected therewith.

Please change the correspondence address for the above-identified application to:

☐ The above-mentioned Customer Number.

OR

☐ Practitioners at Customer Number
☐ Firm or
Individual Name

Address

Address

City

State

ZIP

Country

Telephone

Fax

I am the:

☐ Applicant/Inventor.

☒ Assignee of record of the entire interest. See 37 CFR 3.71.

Statement under 37 CFR 3.73(b) is enclosed. (Form PTO/SB/96).

SIGNATURE of Applicant or Assignee of Record


Name	Neuralab Limited, by: Kevin Insley, Vice President
Signature	
Date	August 31, 2001

NOTE: Signatures of all the inventors or assignees of record of the entire interest or their representative(s) are required. Submit multiple forms if more than one signature is required, see below*.

☒ *Total of 1 form is submitted.

Burden Hour Statement: This form is estimated to take 3 minutes to complete. Time will vary depending upon the needs of the individual case. Any Comments on the amount of time you are required to complete this form should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, Washington, DC 20231. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Assistant Commissioner for Patents, Washington, DC 20231.
PA 3167776 v1

RECEIVED
SEP 26 2001
TC 1700



RECEIVED
NOV 05 2001

STATEMENT UNDER 37 CFR 3.73(b)

Applicant/Patent Owner: Dale B. Schenk
Application No./Patent No.: 09/580,015 Filed/Issue Date: May 26, 2000
Entitled: PREVENTION AND TREATMENT OF AMYLOIDOGENIC DISEASE
Neuralab Limited, a corporation
(Name of Assignee) (Type of Assignee, e.g., corporation, partnership, university, government agency, etc.)

states that it is:

1. ☐ the assignee of the entire right, title, and interest; or
2. ☐ an assignee of an undivided part interest

in the patent application/patent identified above by virtue of either:

A. ☐ An assignment from the inventor(s) of the patent application/patent identified above. The assignment was recorded in the Patent and Trademark Office at Reel , Frame , or for which a copy thereof is attached.

OR

B. ☒ A chain of title from the inventor(s), of the patent application/patent identified above, to the current assignee as shown below:

1. From: Dale B. Schenk To : Elan Pharmaceuticals, Inc.
The document was recorded in the United States Patent and Trademark Office at Reel 011203, Frame 0648, or for which a copy thereof is attached.

2. From: Elan Pharmaceuticals, Inc. To : Neuralab Limited
The document was recorded in the United States Patent and Trademark Office at Reel 011203, Frame 0488, or for which a copy thereof is attached.

3. From: To :
The document was recorded in the United States Patent and Trademark Office at Reel , Frame , or for which a copy thereof is attached.

☐ Additional documents in the chain of title are listed on a supplemental sheet.

☐ Copies of assignments or other documents in the chain of title are attached.
[NOTE: A separate copy (i.e., the original assignment document or a true copy of the original document) must be submitted to Assignment Division in accordance with 37 CFR Part 3, if the assignment is to be recorded in the records of the USPTO. See MPEP 302.8]

The undersigned (whose title is supplied below) is empowered to sign this statement on behalf of the assignee.

September 1, 2001
Date

[Signature]
Signature
Kevin Insley
Typed or printed name
Vice President
Title

RECEIVED
SEP 26 2001
TC 1700

Burden Hour Statement: This form is estimated to take 0.2 hours to complete. Time will vary depending upon the needs of the individual case. Any comments on the amount of time you are required to complete this form should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, Washington, DC 20231. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Assistant Commissioner for Patents, Washington, DC 20231.